In patients with early-stage DKD, it demonstrated superior efficacy in reducing urinary albumin compared to losartan (50 mg/day), and the combination therapy with losartan showed significantly better efficacy than monotherapy [123]; A study involving 413 patients with type 2 diabetes (T2D) and DKD confirmed that its combination with irbesartan effectively reduces albuminuria and proteinuria [211]; further analysis of 2054 patients with CKD showed that the drug can reduce proteinuria while preserving kidney function, making it suitable for patients at different stages of kidney disease [210]. This evidence concerns the gene ALB and diabetic kidney disease.